Allogene Therapeutics announced that it will have two poster presentations focused on the importance of lymphodepletion in allogeneic cell therapy at the 65th Annual Meeting of the American Society of Hematology, ASH, taking place December 9-12, 2023 in San Diego, CA. The first poster is a comprehensive safety review of all 85 patients treated in the Phase 1 ALPHA/ALPHA2 studies in relapsed/refractory Large B Cell Lymphoma and follicular lymphoma to characterize the overall safety profile when ALLO-647 is added to standard lymphodepletion. The second poster showcases translational results from ALPHA2 generated through a collaboration with researchers from The University of Texas MD Anderson Cancer Center. This study compared expansion kinetics among 11 allogeneic CAR T recipients treated with investigational ALLO-501A in the ALPHA2 trial.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALLO:
- Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
- Allogene Therapeutics Announces Participation in November Investor Conferences
- Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023
- Allogene Therapeutics appoints Geoffrey Parker as CFO
- Allogene Therapeutics participates in a conference call with JPMorgan